Iovance Biotherapeutics Q3 net loss narrows 76% year over year to $22.27 million
IOVA•Iovance Biotherapeutics’ third-quarter 2026 net loss narrowed 76% year over year to $22.27 million, while revenue rose 80% to $121.47 million. The company maintained its 2026 revenue guidance of $410 million to $420 million and plans a supplemental approval application for lifileucel in 2027.
1. Quarterly results
Iovance Biotherapeutics reported a third-quarter 2026 net loss of $22.27 million, down 76% year over year. Revenue climbed 80% to $121.47 million.
2. Outlook and application
The company maintained its full-year 2026 revenue guidance of $410 million to $420 million. It plans to submit a supplemental approval application for lifileucel in non-squamous metastatic non-small-cell lung cancer in 2027.
